| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endometriosis | 3 | 2019 | 24 | 1.260 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2012 | 18 | 1.040 |
Why?
|
| Macaca mulatta | 7 | 2019 | 340 | 0.980 |
Why?
|
| Homeodomain Proteins | 4 | 2012 | 53 | 0.960 |
Why?
|
| Whole-Body Irradiation | 4 | 2019 | 58 | 0.930 |
Why?
|
| Immunoglobulin Class Switching | 3 | 2013 | 5 | 0.850 |
Why?
|
| Animals | 40 | 2020 | 8199 | 0.840 |
Why?
|
| B-Lymphocytes | 4 | 2013 | 79 | 0.830 |
Why?
|
| Macaca fascicularis | 4 | 2019 | 542 | 0.800 |
Why?
|
| T-Lymphocytes | 6 | 2019 | 140 | 0.720 |
Why?
|
| Mice | 22 | 2020 | 2571 | 0.640 |
Why?
|
| Endometrium | 1 | 2019 | 44 | 0.600 |
Why?
|
| Transcription, Genetic | 1 | 2019 | 140 | 0.560 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2018 | 7 | 0.560 |
Why?
|
| Energy Metabolism | 1 | 2019 | 153 | 0.560 |
Why?
|
| Iron | 1 | 2018 | 94 | 0.540 |
Why?
|
| Blood Platelets | 4 | 2020 | 59 | 0.530 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2017 | 42 | 0.530 |
Why?
|
| Mitochondria | 1 | 2019 | 211 | 0.530 |
Why?
|
| Lupus Erythematosus, Systemic | 6 | 2015 | 149 | 0.500 |
Why?
|
| Platelet Aggregation | 2 | 2020 | 30 | 0.480 |
Why?
|
| Nuclear Pore Complex Proteins | 2 | 2012 | 5 | 0.470 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2012 | 16 | 0.470 |
Why?
|
| Transcription Factors | 2 | 2015 | 183 | 0.450 |
Why?
|
| Citric Acid | 1 | 2014 | 6 | 0.440 |
Why?
|
| Hirudins | 1 | 2014 | 11 | 0.440 |
Why?
|
| Heparin | 1 | 2014 | 65 | 0.430 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 63 | 0.430 |
Why?
|
| Antibody Formation | 2 | 2019 | 47 | 0.400 |
Why?
|
| Antibody Diversity | 1 | 2013 | 1 | 0.390 |
Why?
|
| H-2 Antigens | 1 | 2013 | 8 | 0.390 |
Why?
|
| Gene Fusion | 1 | 2012 | 4 | 0.380 |
Why?
|
| Translocation, Genetic | 1 | 2012 | 20 | 0.380 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2012 | 25 | 0.380 |
Why?
|
| DNA Repair | 1 | 2012 | 55 | 0.370 |
Why?
|
| Repressor Proteins | 3 | 2015 | 50 | 0.360 |
Why?
|
| Leukemia | 2 | 2012 | 38 | 0.350 |
Why?
|
| Histone Deacetylases | 3 | 2015 | 8 | 0.340 |
Why?
|
| Hydroxamic Acids | 3 | 2015 | 21 | 0.330 |
Why?
|
| Nitrites | 3 | 2020 | 22 | 0.320 |
Why?
|
| Leukemia, Experimental | 1 | 2009 | 3 | 0.310 |
Why?
|
| Retroviridae | 1 | 2009 | 15 | 0.310 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 17 | 0.310 |
Why?
|
| Mice, Transgenic | 6 | 2017 | 257 | 0.300 |
Why?
|
| Mesangial Cells | 3 | 2013 | 9 | 0.290 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2012 | 24 | 0.290 |
Why?
|
| Radiation Injuries, Experimental | 3 | 2019 | 37 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2013 | 246 | 0.280 |
Why?
|
| Gamma Rays | 2 | 2019 | 25 | 0.270 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2015 | 60 | 0.260 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2017 | 20 | 0.260 |
Why?
|
| Female | 18 | 2019 | 19942 | 0.250 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2019 | 100 | 0.250 |
Why?
|
| Pre-Eclampsia | 2 | 2019 | 62 | 0.250 |
Why?
|
| Species Specificity | 2 | 2019 | 98 | 0.250 |
Why?
|
| MicroRNAs | 3 | 2013 | 181 | 0.240 |
Why?
|
| Aging | 1 | 2012 | 942 | 0.240 |
Why?
|
| Gastrointestinal Diseases | 2 | 2020 | 50 | 0.240 |
Why?
|
| Cell Proliferation | 5 | 2019 | 603 | 0.230 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 99 | 0.230 |
Why?
|
| Disease Models, Animal | 9 | 2020 | 1083 | 0.230 |
Why?
|
| Enzyme Inhibitors | 3 | 2015 | 174 | 0.220 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 595 | 0.210 |
Why?
|
| Lameness, Animal | 1 | 2004 | 1 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 7 | 2017 | 792 | 0.210 |
Why?
|
| Carnivora | 1 | 2004 | 2 | 0.210 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2004 | 2 | 0.210 |
Why?
|
| Spinal Cord Compression | 1 | 2004 | 7 | 0.210 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2019 | 83 | 0.210 |
Why?
|
| Interleukin-6 | 3 | 2013 | 224 | 0.210 |
Why?
|
| Fluorodeoxyuridylate | 2 | 2016 | 22 | 0.210 |
Why?
|
| Decompression, Surgical | 1 | 2004 | 55 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2014 | 211 | 0.190 |
Why?
|
| Microscopy, Confocal | 2 | 2013 | 74 | 0.190 |
Why?
|
| Gene Expression Profiling | 3 | 2015 | 314 | 0.190 |
Why?
|
| Humans | 21 | 2020 | 32274 | 0.180 |
Why?
|
| Flow Cytometry | 2 | 2013 | 183 | 0.180 |
Why?
|
| Nitric Oxide Donors | 1 | 2020 | 8 | 0.170 |
Why?
|
| Blood Coagulation | 1 | 2020 | 15 | 0.170 |
Why?
|
| Klebsiella Infections | 1 | 2020 | 6 | 0.170 |
Why?
|
| Nitric Oxide | 3 | 2020 | 121 | 0.160 |
Why?
|
| Bone Marrow Cells | 2 | 2018 | 114 | 0.160 |
Why?
|
| Oxidative Stress | 2 | 2019 | 255 | 0.160 |
Why?
|
| Calcium | 2 | 2019 | 339 | 0.160 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 478 | 0.150 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2019 | 8 | 0.150 |
Why?
|
| Platelet Activation | 2 | 2020 | 16 | 0.150 |
Why?
|
| Antibodies, Bispecific | 1 | 2019 | 5 | 0.150 |
Why?
|
| Magnetic Field Therapy | 1 | 2019 | 15 | 0.150 |
Why?
|
| Hematopoietic System | 1 | 2019 | 3 | 0.150 |
Why?
|
| Calcium Channels, T-Type | 1 | 2019 | 28 | 0.150 |
Why?
|
| Immunity | 1 | 2019 | 19 | 0.150 |
Why?
|
| Primates | 1 | 2019 | 128 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 65 | 0.140 |
Why?
|
| Immunophenotyping | 2 | 2009 | 46 | 0.140 |
Why?
|
| Mutation | 2 | 2012 | 497 | 0.140 |
Why?
|
| RNA, Messenger | 4 | 2015 | 499 | 0.140 |
Why?
|
| Spleen | 3 | 2015 | 84 | 0.140 |
Why?
|
| Hemodynamics | 1 | 2019 | 164 | 0.140 |
Why?
|
| Peptide Hormones | 1 | 2018 | 10 | 0.140 |
Why?
|
| Fibronectins | 1 | 2018 | 39 | 0.140 |
Why?
|
| Menstrual Cycle | 1 | 2018 | 32 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2018 | 55 | 0.140 |
Why?
|
| Anemia | 1 | 2018 | 50 | 0.140 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 112 | 0.140 |
Why?
|
| Bone Marrow | 1 | 2018 | 68 | 0.140 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 93 | 0.130 |
Why?
|
| Brain Injuries | 1 | 2018 | 75 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 164 | 0.130 |
Why?
|
| Glycerophosphates | 1 | 2017 | 4 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 155 | 0.130 |
Why?
|
| Abdominal Wall | 1 | 2017 | 24 | 0.130 |
Why?
|
| Deoxycytidine | 1 | 2017 | 57 | 0.130 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 42 | 0.130 |
Why?
|
| Lupus Nephritis | 1 | 2017 | 29 | 0.130 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 79 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2014 | 90 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2015 | 7 | 0.120 |
Why?
|
| Extracellular Matrix | 1 | 2018 | 256 | 0.120 |
Why?
|
| Ethylenediamines | 1 | 2016 | 6 | 0.120 |
Why?
|
| Chelating Agents | 1 | 2016 | 16 | 0.120 |
Why?
|
| Apoptosis | 5 | 2017 | 375 | 0.120 |
Why?
|
| Gene Expression | 2 | 2018 | 345 | 0.120 |
Why?
|
| Cell Cycle | 2 | 2013 | 75 | 0.120 |
Why?
|
| Zinc | 1 | 2016 | 29 | 0.120 |
Why?
|
| Lipopolysaccharides | 2 | 2013 | 121 | 0.120 |
Why?
|
| Chorionic Villi | 1 | 2015 | 8 | 0.120 |
Why?
|
| Immunoglobulin G | 2 | 2014 | 129 | 0.120 |
Why?
|
| Macrophages | 2 | 2015 | 207 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 104 | 0.110 |
Why?
|
| Myocardium | 1 | 2016 | 184 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2015 | 131 | 0.110 |
Why?
|
| Pyrimidines | 1 | 2015 | 77 | 0.110 |
Why?
|
| Heart | 1 | 2016 | 177 | 0.110 |
Why?
|
| Platelet Function Tests | 1 | 2014 | 7 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2015 | 41 | 0.110 |
Why?
|
| Hemoglobins | 1 | 2014 | 45 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2015 | 54 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2014 | 41 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2013 | 839 | 0.100 |
Why?
|
| E2F2 Transcription Factor | 1 | 2013 | 1 | 0.100 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 274 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2014 | 122 | 0.100 |
Why?
|
| Signal Transduction | 3 | 2014 | 727 | 0.100 |
Why?
|
| Collagen | 1 | 2014 | 229 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 556 | 0.100 |
Why?
|
| NF-kappa B | 1 | 2013 | 84 | 0.100 |
Why?
|
| Cell Line | 4 | 2019 | 454 | 0.100 |
Why?
|
| Blotting, Western | 2 | 2013 | 299 | 0.100 |
Why?
|
| Neoplasms | 2 | 2019 | 754 | 0.100 |
Why?
|
| Interleukin-4 | 1 | 2013 | 22 | 0.100 |
Why?
|
| Mice, Inbred Strains | 1 | 2013 | 55 | 0.100 |
Why?
|
| Lymphopoiesis | 1 | 2012 | 4 | 0.090 |
Why?
|
| Lymphopenia | 1 | 2012 | 11 | 0.090 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2012 | 9 | 0.090 |
Why?
|
| Thymidylate Synthase | 1 | 2012 | 15 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 58 | 0.090 |
Why?
|
| Mice, Inbred NZB | 3 | 2017 | 4 | 0.090 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 489 | 0.080 |
Why?
|
| Phalaris | 1 | 2010 | 1 | 0.080 |
Why?
|
| Cattle Diseases | 1 | 2010 | 3 | 0.080 |
Why?
|
| Haemonchiasis | 1 | 2010 | 1 | 0.080 |
Why?
|
| Haemonchus | 1 | 2010 | 1 | 0.080 |
Why?
|
| Sheep Diseases | 1 | 2010 | 3 | 0.080 |
Why?
|
| Male | 6 | 2019 | 19437 | 0.080 |
Why?
|
| Plant Oils | 1 | 2010 | 17 | 0.080 |
Why?
|
| Blotting, Southern | 1 | 2009 | 22 | 0.080 |
Why?
|
| Leukemia, B-Cell | 1 | 2009 | 5 | 0.080 |
Why?
|
| Kidney | 1 | 2014 | 521 | 0.080 |
Why?
|
| ras Proteins | 1 | 2009 | 10 | 0.080 |
Why?
|
| Cell Differentiation | 2 | 2014 | 461 | 0.080 |
Why?
|
| Platelet Adhesiveness | 2 | 2020 | 21 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 762 | 0.070 |
Why?
|
| U937 Cells | 1 | 2007 | 6 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2019 | 3416 | 0.070 |
Why?
|
| Base Sequence | 1 | 2007 | 252 | 0.060 |
Why?
|
| Amino Acid Sequence | 1 | 2007 | 290 | 0.060 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 359 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 253 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 79 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 114 | 0.060 |
Why?
|
| Aqueous Humor | 1 | 2005 | 3 | 0.060 |
Why?
|
| Acetylation | 2 | 2017 | 14 | 0.060 |
Why?
|
| DNA Damage | 2 | 2017 | 90 | 0.060 |
Why?
|
| Horses | 1 | 2005 | 18 | 0.060 |
Why?
|
| Vitreous Body | 1 | 2005 | 10 | 0.060 |
Why?
|
| Doxycycline | 1 | 2005 | 26 | 0.060 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2005 | 1 | 0.060 |
Why?
|
| HTLV-I Infections | 1 | 2005 | 1 | 0.060 |
Why?
|
| Proviruses | 1 | 2005 | 2 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 106 | 0.060 |
Why?
|
| Viral Load | 1 | 2005 | 73 | 0.060 |
Why?
|
| Ataxia | 1 | 2004 | 5 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 150 | 0.050 |
Why?
|
| Pregnancy | 2 | 2019 | 961 | 0.050 |
Why?
|
| Mice, Inbred MRL lpr | 2 | 2015 | 3 | 0.050 |
Why?
|
| Cell Line, Tumor | 2 | 2017 | 729 | 0.050 |
Why?
|
| Organ Specificity | 2 | 2019 | 80 | 0.050 |
Why?
|
| Body Weight | 2 | 2016 | 323 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 2 | 2014 | 17 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2005 | 324 | 0.050 |
Why?
|
| Light | 1 | 2020 | 35 | 0.040 |
Why?
|
| Klebsiella pneumoniae | 1 | 2020 | 14 | 0.040 |
Why?
|
| Adult | 3 | 2019 | 9256 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 907 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2019 | 47 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 53 | 0.040 |
Why?
|
| Lymphocyte Subsets | 1 | 2019 | 7 | 0.040 |
Why?
|
| Thymus Gland | 1 | 2019 | 15 | 0.040 |
Why?
|
| Angiotensinogen | 1 | 2019 | 59 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2019 | 28 | 0.040 |
Why?
|
| Radiometry | 1 | 2019 | 52 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2019 | 29 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 113 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 91 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2019 | 96 | 0.040 |
Why?
|
| Philadelphia Chromosome | 1 | 2017 | 4 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 73 | 0.030 |
Why?
|
| Cytarabine | 1 | 2017 | 59 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 63 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2017 | 43 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 56 | 0.030 |
Why?
|
| Tubulin | 1 | 2017 | 11 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2017 | 55 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 219 | 0.030 |
Why?
|
| Isoenzymes | 1 | 2017 | 67 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2017 | 76 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 897 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 247 | 0.030 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 2016 | 8 | 0.030 |
Why?
|
| Aptamers, Nucleotide | 1 | 2016 | 11 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2016 | 25 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 79 | 0.030 |
Why?
|
| Liposomes | 1 | 2016 | 34 | 0.030 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Protein Precursors | 1 | 2015 | 24 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2015 | 95 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2015 | 19 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2015 | 138 | 0.030 |
Why?
|
| Tissue Culture Techniques | 1 | 2015 | 42 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2015 | 60 | 0.030 |
Why?
|
| Prostate | 1 | 2016 | 88 | 0.030 |
Why?
|
| Kidney Glomerulus | 1 | 2015 | 28 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 717 | 0.030 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 66 | 0.030 |
Why?
|
| Lymphoid Tissue | 1 | 2015 | 11 | 0.030 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 20 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 68 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 78 | 0.030 |
Why?
|
| Mammary Glands, Human | 1 | 2015 | 14 | 0.030 |
Why?
|
| Nitrite Reductases | 1 | 2014 | 3 | 0.030 |
Why?
|
| Carbonic Anhydrases | 1 | 2014 | 4 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2015 | 32 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 48 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 193 | 0.030 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2014 | 10 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2014 | 12 | 0.030 |
Why?
|
| Lipids | 1 | 2016 | 253 | 0.030 |
Why?
|
| Ribonucleotide Reductases | 1 | 2014 | 6 | 0.030 |
Why?
|
| Rats | 1 | 2019 | 1895 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2015 | 97 | 0.030 |
Why?
|
| Thiophenes | 1 | 2014 | 24 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2015 | 129 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 70 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 621 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2014 | 81 | 0.030 |
Why?
|
| Ovariectomy | 1 | 2015 | 202 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2014 | 86 | 0.030 |
Why?
|
| Oligonucleotides | 1 | 2014 | 26 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2014 | 89 | 0.030 |
Why?
|
| Angiotensin II | 1 | 2015 | 241 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 196 | 0.030 |
Why?
|
| Retinoblastoma Protein | 1 | 2013 | 8 | 0.030 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2014 | 24 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 23 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 33 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 20 | 0.030 |
Why?
|
| Proteinuria | 1 | 2014 | 52 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 443 | 0.030 |
Why?
|
| Tristetraprolin | 1 | 2013 | 1 | 0.030 |
Why?
|
| Protein Transport | 1 | 2013 | 80 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 25 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2013 | 59 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 276 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2013 | 250 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 203 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 390 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 591 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2012 | 17 | 0.020 |
Why?
|
| DNA | 1 | 2014 | 223 | 0.020 |
Why?
|
| Lactams, Macrocyclic | 1 | 2012 | 1 | 0.020 |
Why?
|
| Benzoquinones | 1 | 2012 | 5 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2012 | 29 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 26 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 83 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 80 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2012 | 143 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 164 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2012 | 94 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2016 | 623 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 146 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 965 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 2204 | 0.020 |
Why?
|
| Foodborne Diseases | 1 | 2010 | 2 | 0.020 |
Why?
|
| Pons | 1 | 2010 | 7 | 0.020 |
Why?
|
| West Virginia | 1 | 2010 | 16 | 0.020 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 46 | 0.020 |
Why?
|
| Brain Stem | 1 | 2010 | 22 | 0.020 |
Why?
|
| Paresis | 1 | 2010 | 18 | 0.020 |
Why?
|
| Cattle | 1 | 2010 | 116 | 0.020 |
Why?
|
| Parasite Egg Count | 1 | 2010 | 1 | 0.020 |
Why?
|
| Gerbillinae | 1 | 2010 | 2 | 0.020 |
Why?
|
| Hindlimb | 1 | 2010 | 53 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 160 | 0.020 |
Why?
|
| Feces | 1 | 2010 | 41 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 128 | 0.020 |
Why?
|
| Sheep | 1 | 2010 | 194 | 0.020 |
Why?
|
| Spinal Cord | 1 | 2010 | 137 | 0.020 |
Why?
|
| Young Adult | 1 | 2015 | 2648 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 3898 | 0.020 |
Why?
|
| Neurons | 1 | 2010 | 486 | 0.020 |
Why?
|
| Horse Diseases | 1 | 2005 | 1 | 0.010 |
Why?
|
| Uveitis | 1 | 2005 | 2 | 0.010 |
Why?
|
| Biological Availability | 1 | 2005 | 22 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2005 | 55 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2005 | 200 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 186 | 0.010 |
Why?
|
| Rabbits | 1 | 2005 | 219 | 0.010 |
Why?
|
| Aged | 1 | 2014 | 10260 | 0.010 |
Why?
|
| Middle Aged | 1 | 2014 | 11848 | 0.010 |
Why?
|